Literature DB >> 32981836

Immunological approaches to HIV cure.

Adam R Ward1, Talia M Mota2, R Brad Jones3.   

Abstract

Combination antiretroviral therapy (ART) to treat human immunodeficiency virus (HIV) infection has proven remarkably successful - for those who can access and afford it - yet HIV infection persists indefinitely in a reservoir of cells, despite effective ART and despite host antiviral immune responses. An HIV cure is therefore the next aspirational goal and challenge, though approaches differ in their objectives - with 'functional cures' aiming for durable viral control in the absence of ART, and 'sterilizing cures' aiming for the more difficult to realize objective of complete viral eradication. Mechanisms of HIV persistence, including viral latency, anatomical sequestration, suboptimal immune functioning, reservoir replenishment, target cell-intrinsic immune resistance, and, potentially, target cell distraction of immune effectors, likely need to be overcome in order to achieve a cure. A small fraction of people living with HIV (PLWH) naturally control infection via immune-mediated mechanisms, however, providing both sound rationale and optimism that an immunological approach to cure is possible. Herein we review up to date knowledge and emerging evidence on: the mechanisms contributing to HIV persistence, as well as potential strategies to overcome these barriers; promising immunological approaches to achieve viral control and elimination of reservoir-harboring cells, including harnessing adaptive immune responses to HIV and engineered therapies, as well as enhancers of their functions and of complementary innate immune functioning; and combination strategies that are most likely to succeed. Ultimately, a cure must be safe, effective, durable, and, eventually, scalable in order to be widely acceptable and available.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Broadly neutralizing antibodies; HIV cure; Immunotherapies; Latency; T-cells; Target-cell immune resistance

Mesh:

Substances:

Year:  2020        PMID: 32981836     DOI: 10.1016/j.smim.2020.101412

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  11 in total

1.  Hide and seek: for HIV-infected CD4+ T cells, playing well comes with maturity.

Authors:  Louise Leyre; R Brad Jones
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 14.808

2.  Allogeneic MHC-matched T-cell receptor α/β-depleted bone marrow transplants in SHIV-infected, ART-suppressed Mauritian cynomolgus macaques.

Authors:  Jason T Weinfurter; Saritha S D'Souza; Lea M Matschke; Sarah Bennett; Laurel E Kelnhofer-Millevolte; Kran Suknuntha; Akhilesh Kumar; Jennifer Coonen; Christian M Capitini; Peiman Hematti; Thaddeus G Golos; Igor I Slukvin; Matthew R Reynolds
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

3.  Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response.

Authors:  Antonio Astorga-Gamaza; Judith Grau-Expósito; Joaquín Burgos; Jordi Navarro; Adrià Curran; Bibiana Planas; Paula Suanzes; Vicenç Falcó; Meritxell Genescà; Maria J Buzon
Journal:  Elife       Date:  2022-05-26       Impact factor: 8.713

4.  Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response.

Authors:  Guoxin Wu; Paul Zuck; Shih Lin Goh; Jeffrey M Milush; Poonam Vohra; Joseph K Wong; Ma Somsouk; Steven A Yukl; Barbara L Shacklett; Nicolas Chomont; Ashley T Haase; Hiroyu Hatano; Timothy W Schacker; Steven G Deeks; Daria J Hazuda; Peter W Hunt; Bonnie J Howell
Journal:  J Infect Dis       Date:  2021-11-16       Impact factor: 5.226

Review 5.  A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV.

Authors:  María Amparo Assis; Pedro Gabriel Carranza; Emilio Ambrosio
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

6.  Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo.

Authors:  Andrea Gramatica; Roland Schwarzer; William Brantley; Benjamin Varco-Merth; Hannah S Sperber; Philip A Hull; Mauricio Montano; Stephen A Migueles; Danielle Rosenthal; Louise E Hogan; Jeffrey R Johnson; Thomas A Packard; Zachary W Grimmett; Eytan Herzig; Emilie Besnard; Michael Nekorchuk; Feng Hsiao; Steven G Deeks; Michael Snape; Bernard Kiernan; Nadia R Roan; Jeffrey D Lifson; Jacob D Estes; Louis J Picker; Eric Verdin; Nevan J Krogan; Timothy J Henrich; Mark Connors; Melanie Ott; Satish K Pillai; Afam A Okoye; Warner C Greene
Journal:  J Virol       Date:  2021-02-03       Impact factor: 6.549

7.  Plant microRNAs from Moringa oleifera Regulate Immune Response and HIV Infection.

Authors:  Antonella Minutolo; Marina Potestà; Valentina Roglia; Marco Cirilli; Federico Iacovelli; Carlotta Cerva; Joseph Fokam; Alessandro Desideri; Massimo Andreoni; Sandro Grelli; Vittorio Colizzi; Rosario Muleo; Carla Montesano
Journal:  Front Pharmacol       Date:  2021-02-11       Impact factor: 5.810

8.  Editorial: Novel Insights Into a Functional HIV Cure.

Authors:  Luca Sardo; Cristina Parolin; Takeshi Yoshida; Alfredo Garzino-Demo; Taisuke Izumi
Journal:  Front Microbiol       Date:  2021-12-01       Impact factor: 5.640

Review 9.  CD8 + T-cell responses in HIV controllers: potential implications for novel HIV remission strategies.

Authors:  Rachel L Rutishauser; Lydie Trautmann
Journal:  Curr Opin HIV AIDS       Date:  2022-07-01       Impact factor: 4.061

Review 10.  Ethics of HIV cure research: an unfinished agenda.

Authors:  Karine Dubé; John Kanazawa; Jeff Taylor; Lynda Dee; Nora Jones; Christopher Roebuck; Laurie Sylla; Michael Louella; Jan Kosmyna; David Kelly; Orbit Clanton; David Palm; Danielle M Campbell; Morénike Giwa Onaiwu; Hursch Patel; Samuel Ndukwe; Laney Henley; Mallory O Johnson; Parya Saberi; Brandon Brown; John A Sauceda; Jeremy Sugarman
Journal:  BMC Med Ethics       Date:  2021-06-30       Impact factor: 2.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.